The cost-effectiveness of iruplinalkib versus alectinib in anaplastic lymphoma kinase-positive crizotinib-resistant advanced non-small-cell lung cancer patients in China
Open Access
- 15 April 2024
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 12, 1333487
Abstract
Background: Iruplinalkib is a second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) with efficacy in patients with ALK-positive crizotinib-resistant advanced non-small cell lung cancer (NSCLC), which is independently developed by a Chinese pharmaceutical company. This study examined the cost-effectiveness of iruplinalkib versus alectinib in the Chinese healthcare setting.Methods: A partitioned survival model was developed to project the economic and health outcomes. Efficacy was derived using unanchored matching-adjusted indirect comparison (MAIC). Cost and utility values were obtained from the literature and experts’ opinions. Deterministic and probabilistic sensitivity analyses (PSA) were carried out to evaluate the model’s robustness.Results: Treatment with iruplinalkib versus alectinib resulted in a gain of 0.843 quality-adjusted life years (QALYs) with incremental costs of $20,493.27, resulting in an incremental cost-effectiveness ratio (ICER) of $24,313.95/QALY. Parameters related to relative efficacy and drug costs were the main drivers of the model outcomes. From the PSA, iruplinalkib had a 90% probability of being cost-effective at a willingness-to-pay threshold of $37,863.56/QALY.Conclusion: Compared to alectinib, iruplinalkib is a cost-effective therapy for patients with ALK-positive crizotinib-resistant advanced NSCLC.Keywords
This publication has 31 references indexed in Scilit:
- Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2023
- Whether and How Disutilities of Adverse Events were Used in the Economic Evaluation of Drug Therapy for Cancer TreatmentPharmacoEconomics, 2023
- Cancer incidence and mortality in China, 2016Journal of the National Cancer Center, 2022
- Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancerESMO Open, 2022
- Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic EvaluationsValue in Health, 2022
- Update 2020: Management of Non-Small Cell Lung CancerLung, 2020
- A Systematic Review of Economic Evaluations Assessing the Cost-Effectiveness of Licensed Drugs Used for Previously Treated Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) Negative Advanced/Metastatic Non-Small Cell Lung CancerClinical Drug Investigation, 2019
- Cost-Effectiveness Thresholds: the Past, the Present and the FuturePharmacoEconomics, 2018
- Economic burden of patients affected by non-small cell lung cancer (NSCLC): the LIFE studyJournal of Cancer Research and Clinical Oncology, 2017
- Health state utilities associated with attributes of treatments for hepatitis CThe European Journal of Health Economics, 2014